Considering the key role of cAMP and PI3K/Akt pathways in cardio-renal diseases, obesity, and T2DM, GLP-1 RA could be a potential pharmacological tool in a wide range of patients, including those with cancer and associated cardiovascular diseases [24,25]. This evidence concerns the gene AKT1 and obesity due to melanocortin 4 receptor deficiency.